Dr. Sonja D. Bartolome, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 123
Licensed in Texas since 2010, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
TX license N5556 (first issued 2010; active) -
Critical Care Medicine (Internal Medicine) Physician
TX license N5556 (first issued 2010; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 123
- Services billed
- 272
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 103 | 37 |
| Established patient office or other outpatient visit, 20-29 minutes | 45 | 36 |
| Critical care, first 30-74 minutes | 33 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 26 | 26 |
| New patient office or other outpatient visit, 45-59 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Opsumit (macitentan) | 202 |
| Tadalafil | 110 |
| Adempas (riociguat) | 60 |
| Furosemide Other prescribers in Dallas, TX | 60 |
| Eliquis (apixaban) Other prescribers in Dallas, TX | 46 |
| Potassium Chloride Other prescribers in Dallas, TX | 38 |
| Uptravi (selexipag) | 35 |
| Torsemide Other prescribers in Dallas, TX | 34 |
| Sildenafil Citrate Other prescribers in Dallas, TX | 33 |
| Winrevair (sotatercept-csrk) | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 23 payments worth $13,662 in total to this clinician.
| Merck Sharp & Dohme LLC | $5,751 |
|---|---|
| Chiesi USA, Inc. | $4,753 |
| United Therapeutics Corporation | $2,802 |
| Liquidia Technologies, Inc. | $166 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $148 |
| Sandoz Inc. | $42.41 |
| Consulting Fee | $11,200 |
|---|---|
| Travel and Lodging | $1,256 |
| Food and Beverage | $1,206 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Oct 27, 2025 | Consulting Fee | $4,480 |
| Chiesi USA, Inc. Dec 3, 2025 | Consulting Fee | $4,200 |
| United Therapeutics Corporation Oct 18, 2025 | Consulting Fee | $2,520 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind | $410 |
| Chiesi USA, Inc. Dec 3, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $337 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind | $267 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Travel and Lodging travel to Chicago, IL | $150 |
| Chiesi USA, Inc. Dec 3, 2025 | Travel and Lodging travel to BOSTON, MA | $92.51 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $67,192 in research payments for these studies, mostly to the institutions running them.
- A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics Corporation · Completed · NCT03626688 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
United Therapeutics Corporation · Enrolling by invitation · NCT03683186
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.